The COVID-19 pandemic has generated an overuse of antimicrobials in critically ill patients. Acinetobacter baumannii frequently causes nosocomial infections, particularly in intensive care units (ICUs), where the incidence has increased over time. Since the WHO declared the COVID-19 pandemic on 12 March 2020, the disease has spread rapidly, and many of the patients infected with SARS-CoV-2 needed to be admitted to the ICU. Bacterial co-pathogens are commonly identified in viral respiratory infections and are important causes of morbidity and mortality. However, we cannot neglect the increased incidence of antimicrobial resistance, which may be attributed to the excess use of antimicrobial agents during the COVID-19 pandemic. Patients with COVID-19 could be vulnerable to other infections owing to multiple comorbidities with severe COVID-19, prolonged hospitalization, and SARS-CoV-2-associated immune dysfunction. These patients have acquired secondary bacterial infections or superinfections, mainly bacteremia and urinary tract infections. This review will summarize the prevalence of A. baumannii coinfection and secondary infection in patients with COVID-19.
【저자키워드】 COVID-19, antimicrobial resistance, infections, Acinetobacter baumannii, 【초록키워드】 severe COVID-19, Hospitalization, COVID-19 pandemic, Infection, intensive care unit, antimicrobial, ICU, Spread, Prevalence, respiratory infection, urinary tract infections, Patient, morbidity and mortality, incidence, critically ill patients, Bacteremia, immune dysfunction, Nosocomial infections, secondary bacterial infection, ICUs, Acinetobacter, antimicrobial agent, the patient, the disease, in viral, cause, the WHO, infected with SARS-CoV-2, multiple comorbidity, patients with COVID-19, with COVID-19, 【제목키워드】 Acinetobacter, time,